XML 76 R66.htm IDEA: XBRL DOCUMENT v3.21.2
Segment Information - Reportable Segment Information (Detail) - USD ($)
$ in Millions
3 Months Ended 6 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2021
Jun. 30, 2020
Net sales:        
Net sales $ 3,089 $ 1,199 $ 5,554 $ 2,546
Segment Adjusted Operating EBITDA        
Other Depreciation and Amortization 322 80 564 161
Restructuring and other charges, net (24) (2) (28) (7)
Losses on sale of assets 0 0 0 (1)
Severance Costs (3) 0 (6) 0
Interest expense (77) (32) (142) (64)
Other income, net 11 16 18 5
Income before taxes 44 104 (10) 257
Segment Adjusted Operating EBITDA 679 239 1,248 542
Shareholder Activism Related Costs 0 0 (7) 0
Business Divestiture Costs (5) 0 (5) 0
Corporate and Other        
Segment Adjusted Operating EBITDA        
Restructuring and other charges, net (24) (2) (28) (7)
Losses on sale of assets 0 0 0 (1)
Compliance Review and Legal Defense Costs 0 0 0 (1)
Health & Biosciences        
Segment Adjusted Operating EBITDA        
Restructuring and other charges, net (4) 0 (4) 0
Pharma Solutions        
Segment Adjusted Operating EBITDA        
Restructuring and other charges, net (1) 0 (1) 0
Taste        
Segment Adjusted Operating EBITDA        
Restructuring and other charges, net (17) (2) (20) (7)
Scent [Member]        
Segment Adjusted Operating EBITDA        
Restructuring and other charges, net (2) 0 (3) 0
Operating Segments | Health & Biosciences        
Net sales:        
Net sales 639 34 1,065 68
Segment Adjusted Operating EBITDA        
Segment Adjusted Operating EBITDA 190 10 318 19
Operating Segments | Pharma Solutions        
Net sales:        
Net sales 232 0 394 0
Segment Adjusted Operating EBITDA        
Segment Adjusted Operating EBITDA 48 0 91 0
Operating Segments | Taste        
Net sales:        
Net sales 1,668 690 2,976 1,462
Segment Adjusted Operating EBITDA        
Segment Adjusted Operating EBITDA 324 142 594 318
Operating Segments | Scent [Member]        
Net sales:        
Net sales 550 475 1,119 1,016
Segment Adjusted Operating EBITDA        
Segment Adjusted Operating EBITDA 117 87 245 205
Nutrition & Biosciences, Inc        
Segment Adjusted Operating EBITDA        
Transaction related costs (2)   (91)  
Nutrition & Biosciences, Inc | Corporate and Other        
Segment Adjusted Operating EBITDA        
Integration-related costs (17) (23) (54) (33)
N&B Inventory Step-Up Costs (195) 0 (377) 0
Transaction related costs (2) (11) (91) (16)
Frutarom | Corporate and Other        
Segment Adjusted Operating EBITDA        
Integration-related costs $ (1) $ (3) $ (2) $ (7)